What is the most appropriate inpatient management plan for a 65‑year‑old patient with nicotine dependence presenting with hypertensive urgency, acute coronary syndrome, and new‑onset heart failure with reduced ejection fraction who is not receiving guideline‑directed medical therapy?

Immediate Initiation of Quadruple Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction

This patient requires immediate initiation of all four foundational HFrEF medications during hospitalization: an ACE inhibitor (or ARB), a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), a mineralocorticoid receptor antagonist, and diuretics for congestion management, along with aggressive blood pressure control, dual antiplatelet therapy for the acute coronary syndrome, high-intensity statin therapy, and comprehensive smoking cessation pharmacotherapy. 1, 2, 1

Immediate Priorities (First 24 Hours)

1. Acute Coronary Syndrome Management

• Immediate coronary angiography with intent for revascularization given the acute coronary syndrome presentation 2
• Dual antiplatelet therapy (DAPT): Aspirin 75-100 mg plus ticagrelor or prasugrel (or clopidogrel if others contraindicated) for 12 months 2
• High-intensity statin therapy started immediately unless contraindicated, targeting LDL-C <1.8 mmol/L (70 mg/dL) 2
• Avoid intravenous beta-blockers if hypotension, acute heart failure, or severe bradycardia present 2

2. Hypertensive Urgency Control

• Intravenous vasodilators (nitroglycerin preferred) for rapid blood pressure reduction, as hypertensive acute heart failure is primarily a vascular redistribution problem rather than pure volume overload 3
• Target gradual blood pressure reduction to avoid precipitous drops that compromise coronary perfusion
• Treatment of hypertension is Class I, Level A recommendation to prevent further heart failure progression 1

3. Acute Heart Failure Stabilization

• Diuretics (loop diuretics) for symptomatic congestion relief - Class I, Level B recommendation 1
• Assess volume status carefully; if diuretic resistance develops, consider sequential nephron blockade 3
• Transthoracic echocardiography to confirm reduced ejection fraction and assess for mechanical complications 1

Foundational GDMT Initiation (Within 24-48 Hours Once Stabilized)

The evidence is unequivocal that all four medication classes should be initiated during hospitalization, not delayed until outpatient follow-up. Each provides at least 20% mortality reduction, and beta-blockers, MRAs, and neprilysin inhibitors specifically reduce sudden cardiac death risk 4.

Core Quadruple Therapy:

1. ACE Inhibitor (or ARB if ACE-I not tolerated)

• Start within first 24 hours once hemodynamically stable 2, 1
• Class I, Level A recommendation for HFrEF and post-MI patients 1, 2, 1
• Begin low dose and uptitrate to target doses
• Monitor potassium and renal function

2. Beta-Blocker (carvedilol, metoprolol succinate, or bisoprolol)

• Start once patient stabilized (not during acute decompensation with hypotension) 2, 1
• Class I, Level A recommendation for HFrEF 1
• Provides 20%+ mortality reduction and reduces sudden death 4
• Begin low dose and uptitrate gradually

3. Mineralocorticoid Receptor Antagonist (spironolactone or eplerenone)

• Class I, Level A recommendation for symptomatic HFrEF with LVEF ≤35% 1
• Contraindicated if serum potassium >5.0 mmol/L or severe renal dysfunction 1
• Requires regular monitoring of potassium and renal function
• Provides meaningful mortality reduction (20%+) 4

4. Diuretics

• Continue as needed for congestion management 1
• Adjust dose based on symptoms and volume status
• Can be temporarily discontinued in euvolemic patients

Critical Medication to Avoid:

Do NOT use diltiazem or verapamil - Class III, Level C recommendation as they increase risk of heart failure worsening and hospitalization 1

Smoking Cessation Strategy

Combination pharmacotherapy plus behavioral intervention is essential and provides cardiovascular benefit beyond smoking cessation alone.

• Nicotine replacement therapy PLUS prescription pharmacotherapy (varenicline or bupropion) 5, 6
• Recent real-world evidence shows adding varenicline or bupropion to NRT after ACS significantly reduces 1-year mortality (HR 1.26), MACE (HR 1.16), and heart failure exacerbations (HR 1.16) compared to NRT alone 5
• Varenicline preferred over bupropion when possible, as bupropion showed higher rates of new-onset depression 5
• Behavioral counseling sessions should accompany pharmacotherapy 2, 6
• Class I, Level A recommendation for repeated smoking cessation advice and support 2

Important caveat: Nicotine itself causes direct cardiovascular toxicity through oxidative stress, endothelial dysfunction, and sympathetic activation independent of combustion products 7, 8. This underscores the urgency of complete cessation, not just switching to non-combustible products.

Additional Management Considerations

Gastrointestinal Protection:

• Proton pump inhibitor recommended with DAPT given high bleeding risk 2

Cardiac Rehabilitation:

• Enrollment in cardiac rehabilitation program - Class I, Level A recommendation 2
• Improves outcomes and facilitates medication uptitration

Device Therapy Evaluation (Not Immediate):

• ICD consideration after ≥3 months of optimal medical therapy if LVEF remains ≤35% and NYHA Class II-III 1
• NOT within 40 days of MI - Class III, Level A recommendation 1
• CRT evaluation if QRS ≥130 msec with LBBB morphology after medical optimization 1

Discharge Planning and Follow-Up

Medication Titration Strategy:

Real-world data shows only 1% of patients achieve target doses of all medications simultaneously 9. A forced-titration strategy with close follow-up (within 1-2 weeks) is essential:

• Start all four medication classes at low doses during hospitalization
• Uptitrate systematically every 1-2 weeks to target doses
• Monitor potassium, renal function, blood pressure, and heart rate
• Consider nurse-led titration protocols to overcome clinical inertia 9, 10

Multidisciplinary Heart Failure Management:

• Enrollment in heart failure disease management program improves outcomes 1, 10
• Patient education on self-monitoring, dietary sodium restriction, daily weights
• Close outpatient follow-up within 7-14 days post-discharge

Common Pitfalls to Avoid

1. Delaying GDMT initiation until outpatient setting - All four medication classes should be started in hospital once stabilized
2. Using calcium channel blockers (diltiazem/verapamil) for rate control - these worsen HFrEF outcomes
3. Prescribing NRT alone for smoking cessation - combination with varenicline or bupropion provides superior cardiovascular outcomes
4. Early ICD placement - wait minimum 40 days post-MI and 3 months of optimal medical therapy
5. Inadequate uptitration - most patients never reach target doses without systematic protocols
6. Triple therapy (ACE-I + ARB + MRA) - Class III recommendation due to hyperkalemia and renal dysfunction risk 1